Please login to the form below

Not currently logged in

WHO’s director-general deems vaccine nationalism a “catastrophic moral failure”

Tedros Adhanom Ghebreyesus warns bilateral deals could threaten COVAX facility

The World Health Organization’s (WHO) director-general Tedros Adhanom Ghebreyesus has said that vaccine nationalism poses a “catastrophic moral failure”, adding that high-income countries are jumping “to the front of the queue” in securing COVID-19 vaccines.

The remarks, made during a speech ahead of a meeting of the WHO’s executive board, highlight the inequitable access to vaccines availability between high-income and the low-income countries.

Ghebreyesus noted that over 39 million COVID-19 vaccine doses have now been administered in at least 49 higher-income countries, adding that in one lowest-income country, only 25 doses have been delivered.

“I need to be blunt: the world is on the brink of a catastrophic moral failure – and the price of this failure will be paid with lives and livelihoods in the world’s poorest countries,” he added.

He also commented that bilateral deals signed by high-income countries could threaten the jointly-led COVAX facility by delaying deliveries and creating “exactly the scenario COVAX was designed to avoid, with hoarding, a chaotic market and uncoordinated response and continued social and economic disruption”.

COVAX is the vaccine pillar of the WHO’s ACT Accelerator – a collaborative initiative co-led by the WHO which aims to accelerate development, production and equitable access to COVID-19 tests, treatments and vaccines.

The facility is designed to bolster procurement of promising COVID-19 vaccines to ensure the ‘best possible prices, volumes and timing for all countries’.

Ghebreyesus has now called on countries with bilateral contracts to provide transparency on these deals with COVAX – including on volumes, pricing and delivery dates.

He has also implored higher-income countries to prioritise COVAX’s “place in the queue” by sharing doses with the facility, with particular consideration to be given to health workers and older populations in low-income countries.

“My challenge to all member states is to ensure that by the time World Health Day arrives on 7 April, COVID-19 vaccines are being administered in every country, as a symbol of hope for overcoming both the pandemic and the inequalities that lie at the root of so many global health challenges,” Ghebreyesus added.

In the UK, a total of 4.06 million people have received the first dose of a COVID-19 vaccine, as of 17 January 2021.

The UK has so far approved three COVID-19 vaccines, from Pfizer/BioNTech (an mRNA-based vaccine), AstraZeneca(AZ)/Oxford University and most recently Moderna.

Article by
Lucy Parsons

19th January 2021

From: Healthcare



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...